[1]
R. Warren, “Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)”, J of Skin, vol. 5, no. 1, p. s15, Jan. 2021.